Comparison of Efficacy of Various COVID19 Vaccines Available in India
Author(s): Satvik, Swarupa Chakole and K Himabindu Reddy*
Abstract
At the dawn of the year 2021 India began an extensive vaccination program aiming to vaccinate one hundred percent of its population. India's medication controller has endorsed utilization of COVISHIELD and COVAXIN, several vaccines are yet to be approved but are in various phases of trial and may be available in the near future and are hence assessed in this article. The recent surge in number of COVID-19 cases across Europe even in nations having relatively high vaccination rates demanded a review of the efficacy of the available vaccines in our country. The risk of reinfection and need for booster doses needed to be assessed.
In this review the articles on trials and efficacy of vaccines along with the protection provided against the delta variant of the virus have been assessed and the possible need of revaccinating the public in the event of another wave of infections sweeping the country and the preparedness of the country against the new variant in already vaccinated individuals has also been assessed.
After assessing the cases, vaccine efficacy has reduced but hospitalization rates and mortality ratios are significantly lower in vaccinated population and the second/booster doses have shown significant increase in antibody titres in individuals with low titres after initial dose and significant decrease in hospitalization rates and mortality ratios even with the delta variant.
Vaccinating the public is still the top priority along with other measures including maintain proper hygiene, social distancing, wearing masks to avoid another COVID wave as more mutations like omicron may further decrease the efficacy of currently deployed vaccines.